BioWorld

Nov. 7, 2005

With Flurizan In Phase III, Myriad Bringing In $130M

As lead product Flurizan is being tested in a Phase III trial for Alzheimer's disease, Myriad Genetics Inc. priced a public offering of its common stock to raise $129.5 million. (BioWorld Today) Read More

Introgen Agrees To $20M Partnership With Colgate

Cytori Forms $55M Stem Cell Joint Venture With Olympus

FDA Panel Backs Idea Of HIV Tests Being Sold OTC

Vernalis Paying Mylan $23M For U.S. Rights To Apokyn

Array Partners With Ono For Drug Discovery Work

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Dec. 31, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 31, 2025.

Illustration of magnifying glass looking at cancer in the brain

Researchers discover how glioblastoma tumors dodge chemotherapy

BioWorld MedTech

Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...

Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact

BioWorld

Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...

Big pharma taps fast Asia innovation in search of next Keytruda

BioWorld

Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...